These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 31561846)

  • 21. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).
    Brahmer JR; Govindan R; Anders RA; Antonia SJ; Sagorsky S; Davies MJ; Dubinett SM; Ferris A; Gandhi L; Garon EB; Hellmann MD; Hirsch FR; Malik S; Neal JW; Papadimitrakopoulou VA; Rimm DL; Schwartz LH; Sepesi B; Yeap BY; Rizvi NA; Herbst RS
    J Immunother Cancer; 2018 Jul; 6(1):75. PubMed ID: 30012210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Updates on immunotherapy in non-small cell lung cancer.
    Shimanovsky A; Dasanu CA
    Expert Opin Biol Ther; 2014 Apr; 14(4):411-8. PubMed ID: 24512518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy for non-small-cell lung cancer.
    Thomas A; Jakopovic M
    Expert Opin Biol Ther; 2014 Aug; 14(8):1061-4. PubMed ID: 24878420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy.
    Fujita K; Kim YH; Kanai O; Yoshida H; Mio T; Hirai T
    Respir Med; 2019 Jan; 146():66-70. PubMed ID: 30665520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
    Sgambato A; Casaluce F; Gridelli C
    Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
    Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
    Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy in Lung Cancer: From a Minor God to the Olympus.
    Russo A; McCusker MG; Scilla KA; Arensmeyer KE; Mehra R; Adamo V; Rolfo C
    Adv Exp Med Biol; 2020; 1244():69-92. PubMed ID: 32301011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current status of immunotherapy.
    Suzuki S; Ishida T; Yoshikawa K; Ueda R
    Jpn J Clin Oncol; 2016 Mar; 46(3):191-203. PubMed ID: 26819277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Supportive care in the era of immunotherapies for advanced non-small-cell lung cancer.
    Awada G; Klastersky J
    Curr Opin Oncol; 2018 Mar; 30(2):98-104. PubMed ID: 29303787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers.
    Gelsomino F; Lamberti G; Parisi C; Casolari L; Melotti B; Sperandi F; Ardizzoni A
    Cancer Treat Rev; 2019 Sep; 79():101887. PubMed ID: 31491661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy for small-cell lung cancer: emerging evidence.
    Reck M; Heigener D; Reinmuth N
    Future Oncol; 2016 Apr; 12(7):931-43. PubMed ID: 26882955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view.
    Memon H; Patel BM
    Life Sci; 2019 Sep; 233():116713. PubMed ID: 31386875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer.
    Bianco A; Perrotta F; Barra G; Malapelle U; Rocco D; De Palma R
    Int J Mol Sci; 2019 Oct; 20(19):. PubMed ID: 31590386
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer immunology and melanoma immunotherapy.
    Linck RDM; Costa RLP; Garicochea B
    An Bras Dermatol; 2017; 92(6):830-835. PubMed ID: 29364441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The role of immune checkpoint inhibitors in lung cancer: from clinical trials to clinical practice].
    Wang ZM; Song Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):95-99. PubMed ID: 32062879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy in Lung Cancer: A New Age in Cancer Treatment.
    Corrales L; Scilla K; Caglevic C; Miller K; Oliveira J; Rolfo C
    Adv Exp Med Biol; 2018; 995():65-95. PubMed ID: 30539506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Predictive biomarkers for immune checkpoint inhibitors in non-small-cell lung cancer].
    Fu MJ; Zhou JY
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):87-91. PubMed ID: 32062877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel immunotherapy in the treatment of advanced non-small cell lung cancer.
    Santabarbara G; Maione P; Rossi A; Palazzolo G; Gridelli C
    Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1571-1581. PubMed ID: 27623999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
    Ellis PM; Vella ET; Ung YC
    Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.